Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

ClinicalTrials.gov ID: NCT05153239

Public ClinicalTrials.gov record NCT05153239. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.

Study identification

NCT ID
NCT05153239
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
PharmaMar
Industry
Enrollment
705 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 21, 2022
Primary completion
Apr 9, 2026
Completion
Apr 9, 2026
Last update posted
Aug 9, 2026

2022 – 2026

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
Ironwood Cancer & Research Centers Chandler Arizona 85224
Genesis Cancer and Blood Hot Springs Arkansas 71913
Florida Cancer Specialists - South Fort Myers Florida 33901
Florida Cancer Specialists - North St. Petersburg Florida 33705
Florida Cancer Specialists - Panhandle Tallahassee Florida 32308
Florida Cancer Specialists - East West Palm Beach Florida 33401
Duly Health and Care Joliet Illinois 60435
Norton Cancer Institue, Downtown Louisville Kentucky 40202
Dana-Farber Cancer Institute Boston Massachusetts 02215
Oncology Hematology West, PC (Grand Island) Grand Island Nebraska 68803
Oncology Hematology West, PC dba Nebraska Cancer Specialists Omaha Nebraska 68130
FirstHealth Outpatient Cancer Center Pinehurst North Carolina 28374
Utah Cancer Specialists Salt Lake City Utah 84106
MultiCare Regional Cancer Center - Tacoma Tacoma Washington 98405
Froedtert Hospital/Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 195 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05153239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 9, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05153239 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →